The application of nanotechnology for optimisation of antiretroviral drug delivery, by Invitation (CLINAM, 2014)
Sustained Release Formulations for HIV Therapy, by Invitation (American Society for Nanomedicine, 2014)
Improved Oral Delivery of Antiretroviral Drugs Via A Novel Synthesis of Solid Drug Nanoparticle Form, by Invitation (British Society For Nanomedicine / SelectBio, 2014)
A flexible and scalable alternative to nanomilling for formation of solid drug nanoparticles, by Invitation (NIH/DAIDS, 2014)
Iterating synthesis with pharmacology to accelerate nanomedicine development, by Invitation (British Pharmacological Society, 2013)
How to Target HIV with Nanomedicine, by Invitation (European AIDS Society, 2013)
Improved pharmacokinetics of antiretroviral drugs through formation of solid drug nanoparticles, by Invitation (Pharmacokinetics UK, 2013)
Emerging technologies and challenges for development of long acting therapies, by Invitation (NIH/NIAID/DHHS, 2013)
The role of drug transporters in pharmacokinetics, DDIs and safety of antiretrovirals, by Invitation (Merck, 2013)
The importance of studying drug transporters in HCV drug development, by Invitation (HCV Drug Development Advisory Group, 2013)
The impact of hepatic transporters and pharmacogenetics on the pharmacokinetics of anti-HCV drugs, by Invitation (The International Liver Congress, 2013)
What potential role will novel oral formulations (nanoformulations and nanotechnology) play in HIV, by Invitation (CADO2, 2013)
Nanomedicine in HIV: which perspectives?, by Invitation (University of Turin, 2013)
Recent advances in pharmacogenetics of antiretroviral therapy, by Invitation (University of Belgrade, Belgrade, Serbia, 2012)
Pharmacological assessment of antiretroviral solid drug nanoparticles, by Invitation (Herriot Watt University, Edinburgh, UK, 2012)
Application of solid drug nanoparticles to treatment of Human Immunodeficiency Virus infection, by Invitation (New frontiers: Inaugural meeting of the British Society for Nanomedicine, the Athenaeum, Liverpool, UK, 2012)
Little Big Medicine, by Invitation (International Society on Thrombosis and Haemostasis (ISTH) conference, BT Convention Centre, Liverpool, UK, 2012)
The role of influx and efflux transporters in pharmacokinetics, distribution and safety of antiretro, by Invitation (Merck Global Therapeutics Expert forum, Philadelphia, USA, 2012)
Nanotechnology and Medicine, by Invitation (Liverpool Life Sciences Network - Spring Networking Event, Hard Days Night Hotel, Liverpool, UK, 2012)
Integrated Early Assessment of Nano-particle Risks and Benefits , by Invitation (4th Georgia Symposium on Nanotechnology and Infectious Diseases, Atlanta, USA, 2012)
Use of nanomaterials in drug delivery systems, by Invitation (Modular Training Programme in Applied Toxicology, Nanotoxicology, University of Surrey, Guilford, UK, 2011)
How can we solve the problem of second – line HIV and TB drug interactions?, by Invitation (Médecins Sans Frontières Campaign for Access to Essential Medicines – ART Sequencing Workshop, Geneva, Switzerland, 2011)
Insight into the Pharmacogenetics of Clinically Important Drug Transporters, by Invitation (World Drug Transporter Summit, Boston, USA, 2011)
Pharmacogenomics and Antimicrobial Agents, by Invitation (29th Annual meeting of the European Society for Paediatric Infectious Diseases, The Hague, Netherlands, 2011)
Non-attrition nanoparticles for delivery of antiretroviral drugs, by Invitation (University of Nebraska Medical Centre, Omaha, USA, 2011)
The application of nanotechnology to improve bioavailability of antiretroviral drugs, by Invitation (12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, Florida, USA, 2011)
Pharmacogenomics, by Invitation (6th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. , 2011)
Pharmacogenetic determinants of response to therapy of HIV infection., by Invitation (Molecular Diagnostics 2010, Moscow, Russia, 2010)
Nanoparticles for oral antiretroviral drug delivery: balancing efficacy and safety., by Invitation (The DAIDS Workshop: Nano & Emerging Technologies for HIV, 2010)
The Impact of Pharmacogenetics on Variability in Drug Disposition., by Invitation (Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, USA, 2010)
HIV drug disposition: a pharmacogenetic perspective, by Invitation (Harvard School of Public Health, Program for HIV Prevention and Treatment, Chiang Mai, Thailand, 2010)
Transporter pharmacogenetics - from bench to bedside and back again, by Invitation (DMDG Open Meeting, University of Kent, Canterbury, UK, 2010)
Using Transporter Pharmacogenetics to Improve Patient Care., by Invitation (Clinically Relevant Drug Transporters, CCT Venues Canary Wharf, London UK, 2010)
Nanoparticle Delivery of Antiretroviral Drugs: Opportunities and Safety Concerns., by Invitation (School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK., 2010)
Pharmacogenetics – Upcoming Applications to Patient Care. , by Invitation (17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, USA., 2010)
HIV therapy- New Insights in Pharmacogenetics and Pharmokinetics, by Invitation (Klinik I für Inneren Medizin, Cologne, Germany, 2009)
Nanotechnology-based medicinal products for human use-current issues and future developments., by Invitation (British Toxicology Society Autumn meeting. , 2009)
Pharmacogenetics and pharmacogenomics. , by Invitation (4th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. , 2009)
Investigating the mechanisms of variability in antiretroviral pharmacokinetics., by Invitation (Ottawa Health Research Institute, Ottawa, Ontario, Canada., 2008)
Inter-individual variability in drug disposition, by Invitation (AstraZeneca R&D Charnwood, 2008)
Pharmacogenetics and antiretrovirals: an African Perspective. , by Invitation (UK-Ghana Royal Society HIV workshop, 2008)
Pharmacogenetics and pharmacogenomics, by Invitation (3rd Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy, 2007)
HIV Pharmacology, by Invitation (Liverpool School of Tropical Medicine, 2007)
Pharmocogenomics, by Invitation (British Association for Sexual Health and HIV spotlight meeting, London, UK. , 2007)
The role of nuclear receptors in drug metabolism and disposition., by Invitation (School of Biomedical Sciences, University of Ulster, Coleraine campus, Cromore Road, Coleraine, Co. Londonderry., 2007)
Pharmacogenetics of HIV therapy., by Invitation (Abbott symposium at the BHIVA spring meeting, London, UK., 2007)
Host factors influencing variability in response to antiretroviral drugs., by Invitation (Shenyang Pharmaceutical University, LiaoNing, P.R.China., 2006)
Host Determinants of Antiretroviral Treatment Response., by Invitation (Molecular and Biochemical Parasitology Research Retreat, Whinfell Forest, UK., 2006)
Induction of Intestinal and Hepatic Disposition Genes by Paradigm Nuclear Receptor Ligands, by Invitation (AstraZeneca R&D Charnwood, Loughborough, Leics, UK, 2005)
Pharmacogenetics of Drug Transport / Metabolism in HIV therapy, by Invitation (South West Clinical Pharmacology Meeting, Southampton, UK, 2004)
Relationship between drug transporters and chemokine receptors: relevance to UK-427, 857, by Invitation (Pfizer central Research, Sandwich, Kent, UK, 2004)
In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein, by Invitation (5th Colloquium of the University of Liverpool Centre for Comparative Infectious Diseases, Liverpool, UK, 2004)
The reciprocal role of transporters and chemokine receptors on drug response, by Invitation (College of Pharmacy, Duluth, University of Minnesota, Minneapolis, MN, USA, 2003)
The reciprocal role of transporters and chemokine receptors on drug response, by Invitation (Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2003)
Editorships
British Journal of Pharmacology (Guest Editor , 2013 - 2014)
Nanomedicine: Nanotechnology, Biology and Medicine (Editorial Board, 2012 - present)
Frontiers in Pharmacogenetics and Pharmacogenomics (Review Editor, 2010 - present)
Examination Roles
University of Newcastle upon Tyne, PhD (2012)
University of Surrey, PhD (2011)
Organisations I have been associated with
Presentation to local school students and staff (2012 - present)
Presentation to local business representatives (2012 - present)
British Society for Nanomedicine (2012 - present)
Professional Body Memberships
British Society of Nanomedicine (Chair-Elect, 2012 - present)
Society of Biology (Member, 2012 - present)
British HIV Association (Member, 2007 - present)
British Pharmacological Society (Member, 2005 - present)
International Society for the Study of Xenobiotics (Member, 2003 - present)
Other Administrative or Committee Roles
Professor Owen is Chair of the British Society for Nanomedicine (www.BritishSocietyNanomedicine.org), a member of several committees within the University and is the manager of the Departmental Containment Level III facility.